December 2016 in “Reactions Weekly” Dutasteride and finasteride have equal safety for treating BPH without increased heart risk.
3 citations
,
January 2025 in “Journal of Natural Products” Calancardin B may help reduce inflammation in immune cells.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
April 2023 in “Journal of Investigative Dermatology” Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
April 2026 in “Frontiers in Medicine” Upadacitinib effectively treats psoriasis and lichen planus together.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
February 2023 in “Clinical Toxicology”
5 citations
,
November 2020 in “medRxiv (Cold Spring Harbor Laboratory)” 5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.
May 2017 in “Psychiatric news” BPH medications may increase the risk of self-harm and depression, especially in the first 18 months.
September 2021 in “Assay and drug development technologies” Drug repurposing shows promise for treating many medical conditions.
17 citations
,
June 2020 in “British Journal of Dermatology” Oral mTOR inhibitors often cause skin and hair side effects but usually don't require stopping treatment.
2 citations
,
March 2016 in “The Journal of Urology” Finasteride 1mg linked to diverse symptoms; other treatments improve erectile function in rats.
July 2023 in “Clinical and Experimental Dermatology” Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
January 2025 in “Investigative and Clinical Urology” SHPro® improved urinary symptoms and erectile function in men and is safe.
22 citations
,
September 2020 in “Journal of the American Academy of Dermatology” Apremilast may be a promising long-term treatment for hidradenitis suppurativa.
6 citations
,
April 2022 in “Biomedicine & pharmacotherapy” Using three different drugs together may better treat eye diseases like glaucoma and macular degeneration.
27 citations
,
August 2008 in “Mayo Clinic proceedings” Early recognition and treatment of Peripheral Arterial Disease is crucial to improve survival and health outcomes.
2 citations
,
August 2025 in “Scientific Reports” Pexidartinib often causes liver issues and fatigue, especially in women.
4 citations
,
February 2024 in “Anais Brasileiros de Dermatologia” January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
45 citations
,
January 1981 in “Annals of Internal Medicine” Minoxidil controls blood pressure effectively, but may cause side effects like hypertrichosis.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The serum with microneedling device improves hair loss treatment effectively and safely.
August 2019 in “Key engineering materials” A microemulsion with Carthamus tinctorius extract effectively inhibits 5α-reductase and improves skin and hair follicle delivery.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
1 citations
,
October 2020 in “Journal of Cosmetic Dermatology” Using minoxidil and tofacitinib together can effectively treat severe hair loss.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
June 2014 in “Dermatology Times E-News” An arthritis drug helped a person with severe hair loss regrow their hair.